BCL2 and cancer: Tyrosine kinase inhibitors have been shown to “prime” cancer cells for apoptosis by upregulating pro-apoptotic BH3 proteins like Bim27 making them vulnerable to an inhibitor of Bcl-2 family proteins like AZD0466.